Top

International Journal of Colorectal Disease

Published in:

01-09-2010 | Original Article

Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide

Authors: Xue Hua Pang, Tian Ke Li, Qin Xie, Fu Qian He, De Jun Cui, You Qin Chen, Xiao Li Huang, Hua Tian Gan

Published in: International Journal of Colorectal Disease | Issue 9/2010

Abstract

Background

Neuropeptide Y (NPY) from enteric neurons has been shown to play an important role in immune and inflammatory responses. The purpose of the present study was to investigate the effects of NPY antisense oligodeoxynucleotides (ODNs) on an experimental model of ulcerative colitis (UC).

Methods

NPY antisense ODNs were administered in experimental colitis induced by dextran sulfate sodium (DSS). The disease activity index (DAI) and histological score were observed. The tumor necrosis factor (TNF)-α and NPY levels were measured by enzyme-linked immunosorbent assay. Phosphorylated Akt (p-Akt) expression was determined by immunohistochemical staining. Activated nuclear factor (NF)-κB was assessed by western blot analysis. Myeloperoxidase (MPO) activity was determined by using MPO assay kit.

Results

A significant improvement was observed in DAI and histological score in rats with NPY antisense ODNs, and the increase in NPY and TNF-α levels, MPO activity, and the expression p-Akt and p-NF-κB in rats with DSS-induced colitis was significantly reduced following the administration of NPY antisense ODNs.

Conclusion

The administration of NPY antisense ODNs leads to an amelioration of DSS-induced colitis, suggesting that NPY plays an important role in modulating inflammation in colitis, and NPY antisense ODNs may be a useful therapeutic approach to the treatment of UC.

Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429CrossRefPubMed

Sands BE (2000) Therapy of inflammatory bowel disease. Gastroenterology 118:S68–S82CrossRefPubMed

Villanacci V, Bassotti G, Nascimbeni R, Antonelli E, Cadei M, Fisogni S, Salerni B, Geboes K (2008) Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil 20:1009–1016CrossRefPubMed

Schemann M, Neunlist M (2004) The human enteric nervous system. Neurogastroenterol Motil 16:55–59CrossRefPubMed

von Boyen GBT, Reinshagen M, Steinkamp M, Adler G, Kirsch J (2002) Gut inflammation modulated by the enteric nervous system and neurotrophic factors. Scand J Gastroenterol 37:621–625CrossRef

Hassani H, Lucas G, Rozell B, Ernfors P (2005) Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointest Liver Physiol 288:G550–G556CrossRefPubMed

Chandrasekharan B, Bala V, Kolachala VL, Vijay-Kumar M, Jones D, Gewirtz AT, Sitaraman SV, Srinivasan S (2008) Targeted deletion of neuropeptide Y (NPY) modulates experimental colitis. PLoS ONE 3:e3304CrossRefPubMed

Wheway J, Herzog H, Mackay F (2007) NPY and receptors in immune and inflammatory disease. Curr Top Med Chem 7:1743–1752CrossRefPubMed

Dimitrijevic M, Stanojevic S, Vujic V, Beck-Sickinger A, von Horsten S (2005) Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage function in vitro: counter regulation through Y1 and Y2/5 receptors. Regul Pept 124:163–172CrossRefPubMed

10.

Sung CP, Arleth AJ, Feuerstein GZ (1991) Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. Circ Res 68:314–318PubMed

11.

Zhou JR, Zheng XU, Chun LJ (2008) Neuropeptide Y promotes TGF-β1 production in Raw 264. 7 cells by activation PI3K pathway via Y1 receptor. Neurosci Bull 24:155–159CrossRefPubMed

12.

Custin JA, Ozes ON, Akca H, Pincheira R, Mayo D, Li Q, Guzman JR, Korgaonkar CK, Donner DB (2004) Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 279:1615–1620

13.

Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J (2002) Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 126:116–125CrossRefPubMed

14.

Agrwal S, Zhao Q (1998) Antisense therapeutics. Curr Opin Chem Biol 2:519–528CrossRef

15.

Pirollo KF, Rait A, Sleer LS, Chang EH (2003) Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 99:55–77CrossRefPubMed

16.

Dean NM, Bennett CF (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene 8:9087–9096CrossRef

17.

Tomita N, Morishita R (2004) Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Des 10:797–803CrossRefPubMed

18.

Akabayashi A, Wahlestedt C, Alexander JT, Leibowitz SF et al (1994) Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Mol Brain Res 21:55–61CrossRefPubMed

19.

Xu B, Sahu A, Kalra PS, Crowley WR, Kalra SP (1996) Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger ribonucleic acid antisense oligodeoxynucleotides. Endocrinology 137(1):78–84CrossRefPubMed

20.

Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38:1722–1734CrossRefPubMed

21.

ten Hove T, van den Blink B, Pronk I et al (2002) Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50:507–512CrossRefPubMed

22.

Cooper HS, Murthy SNS, Shah RS, Sederqran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238–249PubMed

23.

Papadakis KA, Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51:289–298CrossRefPubMed

24.

Mantovani A, Muzio M, Garlanda C, Sozzani S, Allavena P (2001) Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found Symp 234:120–131CrossRefPubMed

25.

Thukral C, Cheifetz A, Peppercorn MA (2006) Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 16:2059–2065CrossRef

26.

Ogata H, Hibi T (2003) Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 9:1107–1113CrossRefPubMed

27.

Feagan BG, Reinisch W, Rutgeerts P et al (2007) The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 102:794–802CrossRefPubMed

28.

Blackwell TS, Christman JW (1997) The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 17:3–9PubMed

Title: Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide
Authors: Xue Hua Pang
Tian Ke Li
Qin Xie
Fu Qian He
De Jun Cui
You Qin Chen
Xiao Li Huang
Hua Tian Gan
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 9/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-0964-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2010

Electromechanical characteristics of the human colon in vitro: is there any difference between the right and left colon?

Can DNA sampling from the rectal mucosa be a novel tool for the detection of colorectal cancer?

Measurable learning effects after a 1-week skills course in digestive surgery

Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories

Rho-kinase signalling regulates CXC chemokine formation and leukocyte recruitment in colonic ischemia–reperfusion

Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis